Nesiritide is a synthetic form of brain natriuretic peptide using recombinant DNA technology.
奈西立肽是利用重组DNA技术得到的合成型人类脑利钠肽。
But metaanalyses raised the question of safety with nesiritide therapy, specifically an increased risk of renal dysfunction and mortality.
但是汇总分析发现奈西立肽有引起肾脏损害和死亡率增加的风险。
Blood pressure was lower in the nesiritide group during the first 8-12 hours of the infusion, but not later, and heart rates did not differ significantly between the treatment groups.
在给药的前8 - 12小时,奈西立肽组血压更低,其后无差异,但两组间心率无明显差异。
Blood pressure was lower in the nesiritide group during the first 8-12 hours of the infusion, but not later, and heart rates did not differ significantly between the treatment groups.
在给药的前8 - 12小时,奈西立肽组血压更低,其后无差异,但两组间心率无明显差异。
应用推荐